HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lights, Action, Invest: Icahn Casts Ackman As Herbalife 'Obsessive'

This article was originally published in The Rose Sheet

Executive Summary

William Ackman "may be a smart guy but … he’s developed a very bad case of 'Herbalife obsession'," says Carl Icahn. Herbalife, meanwhile, offers videos on Ackman's "motives."

You may also be interested in...



Health & Wellness Industry Earnings Roundup: Herbalife, Vitamin Shoppe, Church & Dwight

The firm reports nearly 10% growth to $272m in sales of vitamin, oral, skin and hair care, pregnancy tests, condoms, sexual lubricants and other consumer health and personal care products in its fiscal 2016 second-quarter.

Herbalife Claims No Harm, But FTC Hails 'Unprecedented' Settlement's Impact

In addition to imposing a $200m fine, the settlement requires the direct seller to determine compensation for its distributors based on actual retail sales, rather than on the number of additional distributors they bring into their networks, and to show at least 80% of its revenues are to end-users.

Herbalife Sales, Distributor Data Refute Pyramid-Scheme Allegation, Execs Say

Despite regulatory investigations prompted in part by activist investor Bill Ackman, Herbalife reported its 18th consecutive earnings period of record sales, executives with the direct seller say. First-quarter global sales increased 12.4% to $1.3 billion with growth in five of the firm’s six regions.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108525

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel